TET2: A Novel Epigenetic Regulator and Potential Intervention Target for Atherosclerosis.
Sign Up to like & getrecommendations! Published in 2018 at "DNA and cell biology"
DOI: 10.1089/dna.2017.4118
Abstract: Atherosclerosis is the underlying cause of cardio-cerebrovascular disease. However, the mechanisms of atherosclerosis are still unclear. The modification of DNA methylation has an important role in atherosclerosis development. As a member of the Ten-eleven translocation… read more here.
Keywords: tet2 novel; tet2; target atherosclerosis; novel epigenetic ... See more keywords
ClC-3: A Novel Promising Therapeutic Target for Atherosclerosis
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Cardiovascular Pharmacology and Therapeutics"
DOI: 10.1177/10742484211023639
Abstract: Chloride channel 3 (ClC-3), a Cl−/H+ antiporter, has been well established as a member of volume-regulated chloride channels (VRCCs). ClC-3 may be a crucial mediator for activating inflammation-associated signaling pathways by regulating protein phosphorylation. A… read more here.
Keywords: clc novel; clc; therapeutic target; target atherosclerosis ... See more keywords
Oncostatin M: Risks and benefits of a Novel Therapeutic Target for Atherosclerosis.
Sign Up to like & getrecommendations! Published in 2022 at "Current drug targets"
DOI: 10.2174/1389450123666220811101032
Abstract: BACKGROUND Cardiovascular disease (CVD) is a leading cause of death worldwide. It is predicted that approximately 23.6 million people will die from CVDs annually by 2030. Therefore, there is a great need for an effective… read more here.
Keywords: therapeutic target; target atherosclerosis; oncostatin risks; atherosclerosis ... See more keywords